338 related articles for article (PubMed ID: 16385472)
1. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
Blagg BS; Kerr TD
Med Res Rev; 2006 May; 26(3):310-38. PubMed ID: 16385472
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 inhibitors identified from a library of novobiocin analogues.
Yu XM; Shen G; Neckers L; Blake H; Holzbeierlein J; Cronk B; Blagg BS
J Am Chem Soc; 2005 Sep; 127(37):12778-9. PubMed ID: 16159253
[TBL] [Abstract][Full Text] [Related]
3. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
[TBL] [Abstract][Full Text] [Related]
4. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
Moser C; Lang SA; Stoeltzing O
Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells.
Fang S; Fu J; Yuan X; Han C; Shi L; Xin Y; Luo L; Yin Z
Cell Immunol; 2009; 259(1):49-55. PubMed ID: 19560753
[TBL] [Abstract][Full Text] [Related]
6. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?
Khandelwal A; Crowley VM; Blagg BSJ
Med Res Rev; 2016 Jan; 36(1):92-118. PubMed ID: 26010985
[TBL] [Abstract][Full Text] [Related]
7. Derrubone, an inhibitor of the Hsp90 protein folding machinery.
Hadden MK; Galam L; Gestwicki JE; Matts RL; Blagg BS
J Nat Prod; 2007 Dec; 70(12):2014-8. PubMed ID: 18020309
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
9. CYP2E1 degradation by in vitro reconstituted systems: role of the molecular chaperone hsp90.
Goasduff T; Cederbaum AI
Arch Biochem Biophys; 2000 Jul; 379(2):321-30. PubMed ID: 10898951
[TBL] [Abstract][Full Text] [Related]
10. Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells.
Wang X; Heuvelman DM; Carroll JA; Dufield DR; Masferrer JL
Cancer Invest; 2010 Jul; 28(6):635-41. PubMed ID: 20394503
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy.
Gao Z; Garcia-Echeverria C; Jensen MR
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):193-202. PubMed ID: 20205053
[TBL] [Abstract][Full Text] [Related]
12. Molybdate inhibits hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates.
Hartson SD; Thulasiraman V; Huang W; Whitesell L; Matts RL
Biochemistry; 1999 Mar; 38(12):3837-49. PubMed ID: 10090774
[TBL] [Abstract][Full Text] [Related]
13. Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IkappaB kinase (IKK).
Qing G; Yan P; Xiao G
Cell Res; 2006 Nov; 16(11):895-901. PubMed ID: 17088896
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
[TBL] [Abstract][Full Text] [Related]
15. Inside the Hsp90 inhibitors binding mode through induced fit docking.
Lauria A; Ippolito M; Almerico AM
J Mol Graph Model; 2009 Feb; 27(6):712-22. PubMed ID: 19084447
[TBL] [Abstract][Full Text] [Related]
16. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
17. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
Erlichman C
Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
[TBL] [Abstract][Full Text] [Related]
18. p53-independent association between SV40 large T antigen and the major cytosolic heat shock protein, HSP90.
Miyata Y; Yahara I
Oncogene; 2000 Mar; 19(11):1477-84. PubMed ID: 10723140
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery.
Burlison JA; Blagg BS
Org Lett; 2006 Oct; 8(21):4855-8. PubMed ID: 17020320
[TBL] [Abstract][Full Text] [Related]
20. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
